Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial
The PEARL-C1 trial is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.
- Status
- recruiting
- Phase
- Phase 2
- Institution
- University Health Network, Toronto
- Principal investigator
- Sarah Hales, MD, PhD
- Start date
- 2025-07-16
- End date
- 2027-12-02
- Registry ID
- NCT07048743
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.